Hopkinson Craig C. 4

4 · Alkermes plc. · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

EVP R&D, Chief Medical Officer

Transactions

Exercise/Conversion
Ordinary Shares
[F1]
2026-03-02$19.34/sh+5,000$96,700→ 98,389 total
Sale
Ordinary Shares
[F2][F3]
2026-03-02$29.72/sh−9,000$267,485→ 89,389 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
[F1][F4]
2026-03-02−5,000→ 21,356 total
Exercise: $19.34Exp: 2031-02-22→ Ordinary Shares (5,000 underlying)
Award
Employee Stock Option (Right to Buy)
[F5]
2026-03-02+83,037→ 83,037 total
Exercise: $30.25Exp: 2036-03-02→ Ordinary Shares (83,037 underlying)
Award
Restricted Stock Unit Award
[F6][F7]
2026-03-02+38,568→ 38,568 total
→ Ordinary Shares (38,568 underlying)

Footnotes (7)

[F1]This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
[F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
[F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.29 to $30.13. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
[F4]These options are fully vested in accordance with their terms.
[F5]Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 3/2/2027.
[F6]Each restricted stock unit represents a contingent right to receive one ordinary share.
[F7]Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027.

Signature

/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson|2026-03-04

Documents

1 file